Marco centralizes the latest scientific evidence on breast cancer, giving oncologists and breast surgeons instant access to NCCN/ESMO guidelines, biomarker data including HER2, HR and triple-negative subtypes, and results from pivotal trials. The AI agent processes thousands of papers and clinical guidelines to deliver precise, context-specific answers in seconds.
Some answers to questions we often receive
Marco integrates continuously updated NCCN, ESMO, ASCO and SEOM guidelines for breast cancer, covering recommendations by molecular subtype (luminal, HER2+, TNBC), disease stage and specific clinical scenarios including metastatic disease, neoadjuvant settings and survivorship.
Marco includes results from pivotal trials such as monarchE, KATHERINE, KEYNOTE-522, DESTINY-Breast04, OlympiAD and other relevant phase III studies, with synthesis of their clinical practice implications and recommendation levels in current guidelines.
Marco synthesizes evidence on neoadjuvant selection criteria, predictors of pathologic complete response and post-surgical management based on response, integrating current NCCN and ESMO recommendations with data from trials such as NeoALTTO and GeparSepto.
Yes. Marco processes evidence on predictive and prognostic biomarkers in breast cancer including HER2-low, germline and somatic BRCA1/2, PD-L1 expression, hormone receptor status and Ki-67, delivering updated therapeutic implications based on the latest available evidence and guideline recommendations.
Marco is designed for clinical evidence queries without processing patient-identifiable data in its physician-facing mode. Queries address general scientific evidence rather than individual cases, ensuring privacy compliance and regulatory adherence across jurisdictions.
Yes. Marco is specifically designed to democratize access to high-quality clinical evidence. Available via WhatsApp, it requires no special infrastructure, allowing oncologists in any setting to access the same evidence quality as major academic centers.
Oncologists spend hours searching for updated evidence on HER2, BRCA and new agents in breast cancer while recommendations change every quarter.